ARTICLE | Clinical News
PH-10: Completed Phase IIc enrollment
May 30, 2011 7:00 AM UTC
Provectus completed enrollment of more than 90 patients in a single-blind, placebo-controlled, U.S. Phase IIc trial evaluating topical 0.002%, 0.005% and 0.01% formulations of once-daily PH-10 for 28 ...